Drug intelligence / Profile preview

LY3200327

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

LY3200327 is a monoclonal antibody developed by Eli Lilly for the inhibition of interleukin-21 (IL-21). It was investigated primarily as an IL-21 inhibitor for immune system diseases, including systemic lupus erythematosus (SLE). The drug acts as an antagonist to IL-21 and was studied in early-phase clinical trials to evaluate its safety, tolerability, and pharmacokinetics. Development has since been discontinued.

Other names: anti-IL-21 antibodyanti-IL21 antibodyanti-IL 21 antibody

Targets

IL21 (Interleukin-21)

Beyond the preview

Go deeper on LY3200327.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3200327.

Explore the full profile